Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months

ObjectivesTo determine if radiomic features, alone or combined with clinical data, are associated with residual tumour (RT) at surgery, and predict the risk of disease progression within 12 months (PD12) in ovarian cancer (OC) patients.MethodsThis retrospective study enrolled 101 patients according to the following inclusion parameters: cytoreductive surgery performed at our institution (9 May 2007–23 February 2016), assessment of BRCA mutational status, preoperative CT available. Radiomic features of the ovarian masses were extracted from 3D structures drawn on CT images. A phantom experiment was performed to assess the reproducibility of radiomic features. The final radiomic features included in the analysis (n = 516) were grouped into clusters using a hierarchical clustering procedure. The association of each cluster’s representative radiomic feature with RT and PD12 was assessed by chi-square test. Multivariate analysis was performed using logistic regression models. P values < 0.05 were considered significant.ResultsPatients with values of F2-Shape/Compactness1 below the median, of F1- GrayLevelCooccurenceMatrix25/0-1InformationMeasureCorr2 below the median and of F1-GrayLevelCooccurenceMatrix25/-333-1InverseVariance above the median showed higher risk of RT (36%, 36% and 35%, respectively, as opposed to 18%, 18% and 18%). Patients with values of F4-GrayLevelRunLengthMatrix25/-333RunPercentage above the median, of F2 shape/Max3DDiameter below the median and F1-GrayLevelCooccurenceMatrix25/45-1InverseVariance above the median showed higher risk of PD12 (22%, 24% and 23%, respectively, as opposed to 6%, 5% and 6%). At multivariate analysis F2-Shape/Max3DDiameter remained significant (odds ratio (95% CI) = 11.86 (1.41–99.88)). To predict PD12, a clinical radiomics model performed better than a base clinical model.ConclusionThis study demonstrated significant associations between radiomic features and prognostic factors such as RT and PD12.Key Points• No residual tumour (RT) at surgery is the most important prognostic factor in OC.• Radiomic features related to mass size, randomness and homogeneity were associated with RT.• Progression of disease within 12 months (PD12) indicates worse prognosis in OC.• A model including clinical and radiomic features performed better than only-clinical model to predict PD12.

[1]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[2]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[3]  L. Shulman “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations , 2009 .

[4]  T. Jiang,et al.  MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis , 2017, European Radiology.

[5]  Bin Zheng,et al.  Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis , 2016, Acta radiologica.

[6]  W. Cliby,et al.  Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. , 2006, Gynecologic oncology.

[7]  T. Perneger What's wrong with Bonferroni adjustments , 1998, BMJ.

[8]  H. Hricak,et al.  Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. , 2013, Radiology.

[9]  D. Levine,et al.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC) , 2006 .

[10]  Jinzhong Yang,et al.  IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics. , 2015, Medical physics.

[11]  K. Boucher,et al.  The relationship between tumor size and stage in early versus advanced ovarian cancer. , 2013, Medical hypotheses.

[12]  Howard Y. Chang,et al.  Decoding global gene expression programs in liver cancer by noninvasive imaging , 2007, Nature Biotechnology.

[13]  Evis Sala,et al.  Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. , 2017, Radiology.

[14]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[16]  M. Buyse,et al.  Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. , 2011, Current oncology.

[17]  Olivier Gevaert,et al.  Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. , 2012, Radiology.

[18]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[19]  Jing Wang,et al.  Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer , 2017, European Radiology.

[20]  S. Rizzo,et al.  Gynecologic tumors: how to communicate imaging results to the surgeon , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[21]  N. Kushlinskii,et al.  Molecular mechanisms of ovarian carcinoma metastasis: Key genes and regulatory microRNAs , 2017, Biochemistry (Moscow).

[22]  Shota Yamamoto,et al.  ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. , 2014, Radiology.

[23]  L. Mittempergher Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies , 2016, Current Oncology Reports.

[24]  S. Rizzo,et al.  Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. , 2017, Gynecologic oncology.

[25]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[26]  D. Levine,et al.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? , 2007, Gynecologic oncology.

[27]  Harini Veeraraghavan,et al.  A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome , 2017, European Radiology.

[28]  Yanqi Huang,et al.  Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Massimo Bellomi,et al.  CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer , 2015, European Radiology.

[30]  E. Sala,et al.  ESUR guidelines: ovarian cancer staging and follow-up , 2010, European Radiology.